32TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 INTERVIEW satisfaction is boosted by the company’s commitment to quality, sustainability, and comprehensive service offerings, making Grifols a reliable and innovative partner in the CDMO space. Grifols has also been clear about its sustainability goals, including reducing its environmental footprint. How are you integrating sustainable practices into your CDMO operations, particularly in small molecule production? What impact will this have on client partnerships? Grifols is actively integrating sustainable practices into its contract manufacturing operations. Some of the initiatives are: - Setting up energy efficiency technologies and processes to reduce energy consumption across its manufacturing facilities. - Implementing waste reduction strategies, including recycling programs and waste minimization techniques (water recycling systems), to lower its environmental impact. - Ensuring that suppliers adhere to environmental and social responsibility standards, Grifols also shows its commitment to sustainable sourcing of raw materials. These sustainable practices not only help Grifols reduce its environmental footprint but also enhance its reputation as a responsible and forward-thinking partner. This commitment to sustainability can strengthen client partnerships by aligning with the values and goals of clients who prioritize environmental responsibility. It also helps clients meet their own sustainability targets, creating a mutually beneficial relationship. With stricter regulatory scrutiny in the pharma/biotech industry, how is Grifols drawing upon its expertise to ensure compliance and streamline approvals for small molecule products manufactured under its CDMO services? Can you share any recent successes in this area? Grifols employs a quality by design (QbD) approach, integrating quality into the design and development of manufacturing processes from the outset. This ensures that products meet regulatory standards consistently. The company has a dedicated team of regulatory experts who stay abreast of the latest regulatory requirements and guidelines. This team provides comprehensive support, including technical documentation, safety sheets, and certificates of analysis, to facilitate smooth regulatory submissions and approvals. Each production site maintains stringent quality control measures including raw materials control, bioburden testing, and final product control. This rigorous oversight ensures that all products comply with Good Manufacturing Practices (GMP) and other regulatory standards. Grifols has secured authorization for parametric release of parenteral solutions, which allows for product release based on data collected during manufacturing rather than end-product testing. This enhances efficiency and ensures consistent product quality. Grifols manufacturing facilities are accredited by major regulatory bodies, including the FDA, the EMA, and Health Canada. This global compliance framework ensures that products meet the highest regulatory standards across different markets. By integrating these practices, Grifols not only ensures regulatory compliance but also enhances the efficiency of the approval process, thereby strengthening client partnerships and fostering trust. Grifols CDMO parenteral business has stated its intention to increase visibility in 2025. Are there any initiatives or campaigns the company is planning to raise awareness of its CDMO services, notably in the small molecule space? We actively work on several initiatives and campaigns to raise awareness of our CDMO parenteral services. For instance, we regularly participate in major industry conferences and events, such as CPhI worldwide and DCAT, to showcase our CDMO capabilities and network with potential and existing clients. Our team publishes articles in leading industry journals to highlight its expertise and innovative solutions in small molecule production. Grifols leverages digital marketing strategies, including targeted online advertising, social media campaigns to reach a broader audience and educate them about its CDMO services. Sharing client testimonials and success stories helps build credibility and demonstrate the value we bring to our partners.
RkJQdWJsaXNoZXIy MjY2OTA4MA==